
Compare Globe Life's guided growth mix with a curated 34 high quality undervalued stocks that already reflect strong cash flows and balance sheets supporting their earnings targets.
To own Globe Life, you need to believe management can keep growing premium revenue while controlling claims and expenses in its core life and supplemental health lines. The latest guidance, calling for 2026 total premium growth of about 6.5% and normalized EPS growth of roughly 8%, broadly supports that operating thesis rather than reshaping it.
The near term swing factor is still execution on health underwriting and claims volatility, especially as health premium growth is guided well above life. The main risk remains pressure on margins and book value if health obligations, prior period adjustments, or direct to consumer softness persist. This guidance does not remove that concern.
The most relevant update is Globe Life's detailed 2027 outlook for premium mix and net operating earnings per share of US$16.10 to US$17.10. At the midpoint, management projects total premium growth of 6% to 8%, with life premiums in the low single digits and health premiums in the mid teens. This reinforces health as the key volume driver.
That tilt matters for catalysts. A lot now rests on health lines such as Liberty National, Family Heritage and United American delivering the low double digit and high single digit sales growth ranges that the company laid out, while claims stay manageable. If that occurs and the Bermuda reinsurance and AI cost initiatives track to plan, the business has several levers to support its earnings guidance.
Globe Life's analyst narrative points to revenue of US$7.5b and earnings of US$1.4b by 2029, based on an assumed 6.0% yearly gain in revenue and an earnings increase of about US$200m from current earnings of US$1.2b.
Uncover why Globe Life's fair value indicates a potential 18% upside to its current price that could narrow quickly.
One alternate view on Globe Life leans hard into the buyback story. The most optimistic analysts were modeling revenue of about US$7.7b and earnings of roughly US$1.4b by 2029, helped by steady repurchases. Those projections predate the latest 2026 and 2027 guidance, so you should expect that narrative to evolve from here.
Explore 3 other Globe Life fair value estimates, including one that suggests there could be as much as 123% upside from the current price!
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
Once you have a view on Globe Life, it helps to line it up against a broader watchlist so you can see where the most compelling risk and reward profiles really sit.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com